Orna will receive a $65m upfront payment and is eligible to receive potential milestone payments and royalties.

Vertex Pharmaceuticals and Orna Therapeutics have announced a three-year collaboration to develop next-generation gene therapies for sickle cell disease (SCD) and transfusion-dependent beta ...

Orna Therapeutics and Vertex will use lipid nanoparticle system to develop gene-editing therapies for people with SCD and TDT ...

The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle cell and beta thalassemia. Orna Therapeutics (through its wholly owned ...

Johnson & Johnson received Priority Review of nipocalimab in generalized myasthenia gravis. GSK’s B7-H3-targeted ...

Orna Therapeutics (through its wholly owned subsidiary ReNAgade Therapeutics Inc.) announced a three-year strategic research collaboration with Vertex Pharmaceuticals Incorporated (Nasdaq ...

Vertex Pharmaceuticals and Orna Therapeutics announce a $4 billion collaboration to develop in vivo gene editing therapies ...